Sinovac Biotech Ltd.

Sinovac Biotech Ltd.

January 06, 2005 03:20 ET

Sinovac Biotech Ltd. Listed On Halter USX China Index


NEWS RELEASE TRANSMITTED BY CCNMatthews

FOR: SINOVAC BIOTECH LTD.

AMEX SYMBOL: SVA

JANUARY 6, 2005 - 03:20 ET

Sinovac Biotech Ltd. Listed On Halter USX China Index

BEIJING, CHINA--(CCNMatthews - Jan. 6, 2005) - Sinovac Biotech Ltd.
("Sinovac") ("the Company") (AMEX:SVA) is pleased to announce that its
securities has been listed on the Halter USX China Index (HXC), the only
index in the world devoted exclusively to US-listed securities of
companies that derive the majority of their revenues from the People's
Republic of China. Sinovac joins many of China's largest and most
respected companies on this prestigious index.

In addition, the Company has received queries about the recent
fluctuation of its shares price. Sinovac management is unaware of any
material change in the affairs of the Company which would account for
the recent price fluctuation. Management believes that recent price
fluctuations are generally market-related and not related to corporate
or business matters of the Company.

About the Halter USX China Index

The Index, created by the Halter Financial Group and calculated and
distributed by the Amex, is comprised of companies whose common stock is
publicly traded in the United States and the majority of whose business
is conducted within the People's Republic of China. The Halter USX China
Index was created in response to the unique economic opportunities
taking place in China, as well as the current dynamics in the United
States capital markets. While there is strong demand for Chinese equity,
U.S. investors still seek and prefer the transparency offered with a
U.S. listing. For a company to be included in the Halter USX China Index
it must conduct a majority of its business in China, maintain an average
market cap of over $50 million for the preceding 40 trading days, trade
on the NYSE, Amex or NASDAQ and be approved by USX Selection Committee.
Investors can buy the Index by investing in an exchange traded fund
(ETF), the PowerShares Golden Dragon Halter USX China Portfolio (PEAK,
Trade). For more information please visit www.usxchinaindex.com. The
following public companies currently comprise the Halter USX China Index:



Company Name Symbol

Petrochina Co Ltd Adr PTR
China Mobile(hong Kong)ads CHL
Cnooc Ltd Ads CEO
China Unicom Ads CHU
China Petrol & Chem Ads SNP
China Telecom Ads CHA
China Life Insurance Ads LFC
Semiconductor Mfg Intl Ads SMI
Shanda Interactive Enter Ads SNDA
Utstarcom Inc UTSI
Huaneng Power Intl Ads HNP
Aluminum Corp of China Ads ACH
Yanzhou Coal Mining Ads YZC
Netease.com Inc Ads NTES
Sina Corp SINA
51Job Inc. JOBS
Sinopec Shanghai Petrochem Ads SHI
Nam Tai Electronics NTE
Brilliance China Automotive Ad CBA
Tom Online Ads TOMO
Ctrip.com Intl Ads CTRP
Sohu.com Inc SOHU
Guangshen Railway Ads GSH
Sinopec Beijing Yan Petr'h'ads BYH
China Southern Airlines'h'ads ZNH
chinadotcom corp CHINA
China Yuchai Intl CYD
China Eastern Airlines Ads CEA
Jilin Chemical Ind Ads JCC
Intac Intl INTN
KongZhong Corp KONG
Webzen Inc Ads WZEN
China Automotive Sys CAAS
Asiainfo Holdings ASIA
eLong Inc. LONG
Deswell Industries DSWL
China Finance Online JRJC
Linktone Ltd Ads LTON
Asat Holdings Ads ASTT
Radica Games RADA
Qiao Xing Universal Tel XING
Sinovac Biotech Ltd. SVA
Pacificnet Inc. PACT


About Sinovac Biotech Ltd.

Sinovac Biotech Ltd. specializes in the research, development,
commercialization, and sales of human vaccines for infectious illnesses
such as hepatitis A and hepatitis B, influenza, "SARS", and avian flu.
Sinovac is one of the leading emerging biotechnology companies in China.

Sinovac has three vaccines that have completed all three phases of
clinical trials - Hepatitis A, Hepatitis A&B combined, and influenza
(flu). The Hepatitis A vaccine, Healive™, is currently experiencing
strong sales growth in China and applications have been filed for its
sale in nine other countries to date. Sinovac's Hepatitis A&B combined
vaccine, Bilive™, is expected to receive approval to commence sales
in China soon and to achieve similar sales growth to Healive™. The
flu vaccine completed clinical trials in April 2004 and a New Drug
Application has been filed with the SFDA (Chinese FDA). Approval of
Sinovac's flu vaccine is expected in 2005 upon completion of the flu
vaccine production line. Since demand for a safe and effective flu
vaccine in China greatly outstrips supply, sales are expected to
escalate rapidly. Furthermore, since individuals are vaccinated against
the flu on an annual basis, demand will remain high every year.

Sinovac is currently the only company in the world to be conducting
clinical trials for a vaccine to prevent SARS. The Company is also
developing a vaccine targeting avian flu in partnership with the China
Center of Disease Control (CDC).

For further information please refer to the Company's filings with the
SEC on EDGAR or refer to Sinovac's website at www.sinovac.com.

If you would like to receive regular updates on Sinovac please send your
email request to info@sinovac.com.

THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE
MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS
AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE
ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES,
DEVELOPING ADDITIONAL PROJECT INTERESTS, SINOVAC'S ANALYSIS OF
OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT
INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE
"SAFE HARBOR" PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES
LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES WHICH
COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE
FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.

-30-

Contact Information

  • FOR FURTHER INFORMATION PLEASE CONTACT:
    Sinovac Biotech Ltd.
    Investor Relations
    (888) 888-8312 or
    1 604 684-5990 from outside of North America
    info@sinovac.com